Zoetis Inc. (NYSE:ZTS) Shares Purchased by Brown Advisory Inc.

Brown Advisory Inc. boosted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 7.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,408,542 shares of the company's stock after purchasing an additional 312,746 shares during the quarter. Zoetis makes up 1.0% of Brown Advisory Inc.'s investment portfolio, making the stock its 25th biggest holding. Brown Advisory Inc. owned approximately 0.99% of Zoetis worth $725,866,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Schroder Investment Management Group raised its stake in Zoetis by 2.6% in the fourth quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock valued at $40,036,000 after buying an additional 6,169 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after acquiring an additional 120,158 shares during the last quarter. Portside Wealth Group LLC raised its position in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after acquiring an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. lifted its stake in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares during the last quarter. Finally, Horizon Financial Services LLC acquired a new position in Zoetis in the first quarter valued at approximately $380,000. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Performance

Shares of NYSE:ZTS traded down $3.89 on Friday, reaching $154.91. The company's stock had a trading volume of 2,267,443 shares, compared to its average volume of 2,591,358. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock has a market capitalization of $68.97 billion, a P/E ratio of 27.81, a PEG ratio of 2.63 and a beta of 0.91. The stock's 50-day moving average is $161.32 and its two-hundred day moving average is $161.86. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same period in the prior year, the business earned $1.38 EPS. The firm's revenue was up 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.29%. Zoetis's dividend payout ratio is currently 35.91%.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler boosted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Finally, UBS Group dropped their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $212.13.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.18% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.